Dawson James Securities: NeuroMetrix Launches New Product

According to a research report published today by Dawson James Securities, NeuroMetrix Inc. (NASDAQ: NURO) has launched its new product, the NC-stat DPNCheck, for diagnosing diabetic peripheral neuropathy.

Dawson James Securities explained further in the report, “[It] has already made inroads in penetrating its long-established client base of primary care physicians and specialists in the diabetic care market, having signed up over 200 clinicians and shipped initial orders already in 2011. What's more, the Company plans on growing this business throughout 2012, by adding new accounts, and by initiating pilot programs with managed care providers, large self-insured employers, and retail medical clinics, all to reach a target of 1,000 accounts opened by the end of this year. Finally, by conducting and publishing new clinical studies on using the device and establishing a presence at this summer's medical conferences for Diabetes care and Podiatry, the Company is setting the stage for the increasing adoption of reimbursement for the procedure.”

Dawson James Securities maintains its Buy rating and $3 PT on NeuroMetrix, which is currently trading at $0.79.